RadNet (NASDAQ:RDNT – Get Free Report) had its price target boosted by Truist Financial from $90.00 to $94.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Truist Financial’s price target would suggest a potential upside of 23.95% from the stock’s current price.
A number of other research firms have also recently issued reports on RDNT. Jefferies Financial Group restated a “buy” rating on shares of RadNet in a report on Friday, July 31st. Zacks Research lowered RadNet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Barclays decreased their target price on RadNet from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Wednesday, May 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.00.
Check Out Our Latest Research Report on RDNT
RadNet Trading Down 1.9%
RadNet (NASDAQ:RDNT – Get Free Report) last announced its earnings results on Sunday, August 9th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.10. The business had revenue of $622.72 million during the quarter, compared to analyst estimates of $610.87 million. RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The company’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.31 earnings per share. On average, analysts anticipate that RadNet will post 0.52 earnings per share for the current fiscal year.
Insider Buying and Selling
In other RadNet news, Director David L. Swartz sold 2,699 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $53.89, for a total transaction of $145,449.11. Following the sale, the director owned 177,013 shares of the company’s stock, valued at approximately $9,539,230.57. This trade represents a 1.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cornelis Wesdorp sold 4,750 shares of RadNet stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total value of $276,022.50. Following the completion of the transaction, the chief executive officer owned 69,075 shares in the company, valued at $4,013,948.25. This represents a 6.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 5.14% of the company’s stock.
Hedge Funds Weigh In On RadNet
Several institutional investors and hedge funds have recently added to or reduced their stakes in RDNT. BlackRock Inc. bought a new position in shares of RadNet during the 2nd quarter worth approximately $675,768,000. RTW Investments LP boosted its stake in RadNet by 39.9% in the fourth quarter. RTW Investments LP now owns 3,938,500 shares of the medical research company’s stock valued at $281,012,000 after acquiring an additional 1,122,956 shares in the last quarter. Polar Capital Holdings Plc purchased a new position in RadNet in the third quarter worth $63,423,000. Price T Rowe Associates Inc. MD grew its holdings in RadNet by 30.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,699,082 shares of the medical research company’s stock worth $192,581,000 after purchasing an additional 627,936 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of RadNet by 79.7% during the second quarter. Ameriprise Financial Inc. now owns 1,394,552 shares of the medical research company’s stock worth $79,364,000 after purchasing an additional 618,392 shares in the last quarter. Hedge funds and other institutional investors own 77.90% of the company’s stock.
More RadNet News
Here are the key news stories impacting RadNet this week:
- Positive Sentiment: Record revenue and EBITDA: Q2 revenue rose 25% year over year to $622.7 million, exceeding the $610.9 million consensus estimate, while adjusted EBITDA increased 22.7% to a record $99.7 million. RadNet Q2 financial results
- Positive Sentiment: Imaging demand remained strong: Aggregate MRI, CT and PET/CT procedures increased 21.2%, while same-center advanced-imaging volume grew 9.6%. The mix of higher-value procedures improved the Imaging Center segment’s adjusted EBITDA margin to 16.1%.
- Positive Sentiment: Guidance was raised: RadNet increased its 2026 Imaging Center revenue guidance to $2.37 billion-$2.42 billion, adjusted EBITDA guidance to $345 million-$358 million and free-cash-flow guidance to $115 million-$125 million. RadNet healthcare update
- Positive Sentiment: Digital Health is expanding rapidly: Segment revenue climbed 56.5% to $32.4 million, and annual recurring revenue nearly doubled to $105.5 million. A newly FDA-cleared breast-ultrasound AI product and additional health-system partnerships could support future growth.
- Neutral Sentiment: Management’s earnings call highlighted acquisitions, joint ventures and investments in DeepHealth AI and enterprise imaging as long-term growth drivers, but investors are weighing the time required for these initiatives to generate returns. RadNet Q2 earnings call transcript
- Negative Sentiment: Profitability weakened: Adjusted EPS fell to $0.29 from $0.34 a year earlier, although it beat estimates of $0.19. GAAP net income attributable to shareholders also declined to $7.5 million from $14.5 million.
- Negative Sentiment: Digital Health adjusted EBITDA dropped 27.2% to $2.5 million as RadNet increased spending on personnel, infrastructure, sales and research and development. The company also posted a $25.9 million first-half net loss, compared with a $23.5 million loss last year.
- Negative Sentiment: Reported insider activity showed nine open-market sales and no purchases over the past six months, which may add pressure to sentiment at an elevated valuation. RadNet record Q2 results
About RadNet
RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.
Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.
Read More
- Five stocks we like better than RadNet
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
- Tesla’s Energy Business Just Got a SpaceX Demand Signal
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
